CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF)
CUSIP: G1933S101
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Ordinary Shares
- Shares outstanding
- 35,821,764
- Total 13F shares
- 228
- Share change
- -44,205
- Total reported value
- $25
- Price per share
- $0.11
- Number of holders
- 1
- Value change
- -$37,644
- Number of buys
- 1
- Number of sells
- 5
Quarterly Holders Quick Answers
What is CUSIP G1933S101?
CUSIP G1933S101 identifies CASIF - CASI Pharmaceuticals, Inc. - Ordinary Shares in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP G1933S101:
Top shareholders of CASIF - CASI Pharmaceuticals, Inc. - Ordinary Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Panacea Innovation Ltd |
13D/G
|
James Huang |
22%
|
4,651,527
|
$4,698,042 | +$999,856 | 16 Dec 2025 | |
| Wei-Wu He |
13D/G
3/4/5
|
WEI-WU HE, Ph.D. · Director, 10%+ Owner |
53%
|
18,985,535
|
$4,556,528 | +$1,204,800 | 23 Mar 2026 | |
| Zhenfeng M. Chen |
13D/G
|
Chen Zhenfeng |
11%
|
2,255,636
|
$4,150,370 | $0 | 30 Sep 2025 | |
| James Huang |
13D/G
3/4/5
|
Director |
14%
|
2,161,571
|
$3,177,509 | $0 | 30 Jun 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
9.2%
|
1,987,259
|
$2,066,749 | $0 | 31 Dec 2025 | |
| VR Adviser, LLC |
13F
|
Company |
2.8%
|
987,259
|
$839,170 | — | 31 Dec 2025 | |
| SPARKLE BYTE LTD |
13D/G
|
— |
5%
|
1,019,852
|
$775,088 | $0 | 30 Sep 2025 | |
| Ho Chi Sing |
13D/G
|
Zhou Quan |
4.8%
|
992,638
|
$754,405 | $0 | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.37%
|
133,406
|
$113,395 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.12%
|
43,100
|
$36,635 | — | 31 Dec 2025 | |
| Alex Wu |
3/4/5
|
Director |
0.1%
|
34,168
|
$29,042 | — | 18 Mar 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.07%
|
23,787
|
$20,219 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.06%
|
19,935
|
$16,945 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
18,808
|
$15,986 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.04%
|
14,045
|
$11,938 | — | 31 Dec 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.03%
|
9,700
|
$8,000 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
659
|
$560 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
505
|
$429 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
367
|
$312 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
134
|
$114 | — | 31 Dec 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0%
|
133
|
$113 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
25
|
$21 | — | 31 Dec 2025 | |
| Colonial Trust Co / SC |
13F
|
Company |
0%
|
11
|
$9 | — | 31 Dec 2025 | |
| MAI Capital Management |
13F
|
Company |
0%
|
5
|
$5 | — | 31 Dec 2025 |
Institutional Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF) as of Q1 2026
As of 31 Mar 2026,
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
228 shares.
The largest 1 holders included
SIMPLEX TRADING, LLC.
This page lists
1
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
16
Q1 2026 holders
1
Holder diff
-15
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.